Key facts
| Price (PPV) | 158 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbesartanhydrochlorothiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA04 |
| Manufacturer | SUN PHARMACEUTICALS NORTH AFRICA S.A |
| Presentation | Boite de 28 |
| Nature | Médicament |
| Hospital price | 98.70 MAD |
| Data collected on | 9/8/2026 |
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Co-Arapro 300 mg / 12.5 mg (ZENITH PHARMA) contains the same active substance as Co-Irbesar Sun 300 mg / 12.5 mg (Irbesartan | Hydrochlorothiazide) at the same strength, but in a different pack: Boite de 10 at 60.70 MAD, i.e. 6.07 MAD per unit against 5.64 MAD for Co-Irbesar Sun 300 mg / 12.5 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
Same pack size
| Product | Manufacturer | Pack | PPV | Unit price | Difference |
|---|---|---|---|---|---|
| Co-Irvel 300 mg / 12.5 mg | AFRIC-PHAR | Boite de 28 | 158 MAD | 5.64 / unit | — |
| Co-Vepran 300 mg / 12.5 mg | SOTHEMA | Boite de 28 | 158 MAD | 5.64 / unit | — |
Other pack sizes
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Co-Arapro 300 mg / 12.5 mg | ZENITH PHARMA | Boite de 10 | 60.70 MAD | 6.07 / unit |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 10 | 60.70 MAD | 6.07 / unit |
| Co-Icard 300 mg / 12.5 mg | COOPER PHARMA | Boite de 14 | 85 MAD | 6.07 / unit |
| Co-Irvel 300 mg / 12.5 mg | AFRIC-PHAR | Boite de 14 | 85 MAD | 6.07 / unit |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 20 | 88.50 MAD | 4.43 / unit |
| Coavacor 300 mg / 12.5 mg | POLYMEDIC | Boite de 30 | 158.20 MAD | 5.27 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Co-Irbesar Sun 300 mg / 12.5 mg
Co-Irbesar Sun 300 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by SUN PHARMACEUTICALS NORTH AFRICA S.A and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Co-Irbesar Sun 300 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Co-Irbesar Sun 300 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.